MYOM2 and Miyoshi myopathy: In SMM patients, the levels of M protein in the serum are higher than in MGUS (≥3 g/dL), with patients still showing no symptoms and no laboratory signs of end-organ damage, but the risk of progression to MM is approximately 10% per year in the first 5 years [4,5].